RxDoctor Payments Data

David Lamb, MD

Urology · West Columbia, SCNPI 1215961842

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.6%), travel and lodging and other — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Coloplast at 47.8% of the total. Reporting peaked in 2019 at $2,258 and has fallen 88.3% since, to $263 in 2025.

$6,835in general payments, 2019–2025

Across 179 payments — averaging $38.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Boston Scientific$1K
  • AbbVie$434
  • Teleflex LLC$352
  • Olympus America Inc.$344
  • Medtronic$281
  • plus $772 from 18 others

What the payments were for

  • Travel & lodging$2,56338%
  • Food & beverage$4,00759%
  • Other$2654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,835 in reported general payments places this provider in the 70th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$472,164
Medicare patients
821
Services billed
8,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$39,345
GemtesaVibegron49$37,279
Mirabegron ErMirabegron12$5,774
Tamsulosin Hcl306$4,054
Tolterodine Tartrate ErTolterodine Tartrate24$3,298
Finasteride216$2,873
Alfuzosin Hcl ErAlfuzosin Hcl132$2,796
Desmopressin Acetate48$1,493
Solifenacin Succinate27$1,327
Dutasteride28$1,260
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst211$1,188
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$874
Trimethoprim40$780
Ondansetron OdtOndansetron137$755
Oxybutynin Chloride ErOxybutynin Chloride44$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$110$39,34559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 196 urology providers in South Carolina.

Other urology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →